Core Viewpoint - The FRUSICA-2 study results indicate that the combination of fruquintinib and sintilimab may provide a valuable new treatment option for patients with advanced renal cell carcinoma, addressing significant unmet medical needs in this patient population [1][3]. Group 1: Study Overview - The FRUSICA-2 study is a randomized, open-label, positive-controlled registration trial aimed at evaluating the efficacy and safety of fruquintinib combined with sintilimab compared to axitinib or everolimus monotherapy for second-line treatment of advanced renal cell carcinoma [1]. - A total of 234 patients were randomly assigned to receive either the combination therapy or monotherapy [1]. Group 2: Efficacy Results - The median progression-free survival (PFS) for the fruquintinib and sintilimab group was 22.2 months, compared to 6.9 months for the axitinib/everolimus group, with a stratified hazard ratio (HR) of 0.373 and a p-value of <0.0001 [2]. - The objective response rate (ORR) was 60.5% for the combination therapy versus 24.3% for the monotherapy, with an odds ratio of 4.622 and a p-value of <0.0001 [2]. - The median duration of response (DoR) was 23.7 months for the combination group compared to 11.3 months for the monotherapy group [2]. Group 3: Safety Profile - The combination therapy demonstrated a tolerable safety profile, consistent with known characteristics of the treatments, with 71.4% of patients experiencing grade 3 or higher treatment-emergent adverse events (TEAEs) compared to 58.8% in the axitinib/everolimus group [2]. Group 4: Regulatory Progress - Based on the FRUSICA-2 study data, the National Medical Products Administration of China has accepted the new drug application for the combination therapy for patients with locally advanced or metastatic renal cell carcinoma who have previously failed systemic treatment [3].

Core Insights - The FRUSICA-2 study results indicate that the combination of fruquintinib and sintilimab may provide a valuable new treatment option for patients with advanced renal cell carcinoma, addressing significant unmet medical needs in this patient population [1][3] Study Overview - The FRUSICA-2 study is a randomized, open-label, positive-controlled registration trial designed to evaluate the efficacy and safety of fruquintinib and sintilimab compared to axitinib or everolimus as second-line treatments for advanced renal cell carcinoma [1] - A total of 234 patients were randomly assigned to receive either the combination therapy or monotherapy with axitinib or everolimus, with a median follow-up time of 16.6 months as of the final analysis cutoff date [1] Efficacy Results - The median progression-free survival (PFS) for the fruquintinib and sintilimab combination was 22.2 months, compared to 6.9 months for the axitinib/everolimus group, with a stratified hazard ratio (HR) of 0.373 and a p-value of less than 0.0001 [2] - The objective response rate (ORR) was 60.5% for the combination therapy versus 24.3% for the monotherapy group, with an odds ratio of 4.622 and a p-value of less than 0.0001 [2] - The median duration of response (DoR) was 23.7 months for the combination therapy compared to 11.3 months for the monotherapy group [2] Safety Profile - The combination therapy demonstrated a tolerable safety profile, consistent with known characteristics of the treatments, with 71.4% of patients experiencing grade 3 or higher treatment-emergent adverse events (TEAEs) compared to 58.8% in the axitinib/everolimus group [2] Regulatory Progress - Based on the FRUSICA-2 study data, the National Medical Products Administration of China has accepted the new drug application for the combination therapy of fruquintinib and sintilimab for patients with locally advanced or metastatic renal cell carcinoma who have previously failed systemic treatment [3]

Core Viewpoint - The FRUSICA-2 study results indicate that the combination of fruquintinib and sintilimab may provide a valuable new treatment option for patients with advanced renal cell carcinoma, addressing significant unmet medical needs in this patient population [1][3]. Summary by Sections Study Overview - The FRUSICA-2 study is a randomized, open-label, positive-controlled registration trial designed to evaluate the efficacy and safety of fruquintinib combined with sintilimab compared to monotherapy with axitinib or everolimus for second-line treatment of advanced renal cell carcinoma [1]. - A total of 234 patients were randomly assigned to receive either the combination therapy or monotherapy [1]. Efficacy Results - The median progression-free survival (PFS) for the fruquintinib and sintilimab group was 22.2 months, compared to 6.9 months for the axitinib/everolimus group (stratified hazard ratio [HR] 0.373; p < 0.0001) [2]. - The objective response rate (ORR) was 60.5% for the combination therapy versus 24.3% for the monotherapy (odds ratio 4.622; p < 0.0001) [2]. - The median duration of response (DoR) was 23.7 months for the combination group compared to 11.3 months for the monotherapy group [2]. - Efficacy benefits were observed across all prognostic risk groups as defined by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) [2]. Safety Profile - The combination therapy demonstrated a tolerable safety profile, consistent with known characteristics of the treatments [2]. - The proportion of patients experiencing grade 3 or higher treatment-emergent adverse events (TEAEs) was 71.4% in the fruquintinib and sintilimab group, compared to 58.8% in the axitinib/everolimus group [2]. Regulatory Status - Based on the FRUSICA-2 study data, the National Medical Products Administration of China has accepted the new drug application for the combination therapy for patients with locally advanced or metastatic renal cell carcinoma who have previously failed systemic treatment [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） 呋喹替尼聯合信迪利單抗的盲態獨立中心閱片（BICR）評估的中位PFS為22.2個月 ，阿昔替尼/依維莫司組則為6.9 個月（分層風險比 [HR] 0.373 ；分層log-rank檢驗 p <0.0001） 。客觀緩解率（ORR）分別為60.5%對比24.3% （優 勢比 4.622 ， p <0.0001），中位緩解持續時間（DoR）分別為23.7個月對比11.3個月。截至數據截止時，總存活期 數據仍在持續積累中，成熟度約為20%。在根據國際轉移性腎細胞癌數據庫聯盟（IMDC）標準劃分的所有預後風 險組中，均觀察到療效獲益。 呋喹替尼和信迪利單抗的聯合療法展示出可耐受的安全性，並與各項治療的已知特徵保持一致。呋喹替尼和信迪利 單抗組患者發生3級或以上治療期間不良事件（TEAE）的比例為71.4% ...

Group 1 - The report indicates that despite short-term adjustments in the Hong Kong stock market, it remains in a trend of oscillating upward with a solid bottom [1] - The report maintains a positive outlook on AI technology, suggesting that while US tech giants may influence the trading rhythm of Hong Kong's AI sector, the acceleration of China's AI progress offers recovery potential for leading tech stocks in Hong Kong [2] - The report emphasizes a focus on cyclical recovery, with the market awaiting guidance from the Fourth Plenary Session and the 15th Five-Year Plan, suggesting tactical trading in cycles and consumption [2] Group 2 - The report lists a selection of "golden stocks" for October, including Alibaba, Kuaishou, Xiaopeng Motors, and others, with detailed financial metrics such as market capitalization, EPS, and PE ratios for 2026 and 2027 [2][6] - Alibaba is highlighted for its strong cloud business growth driven by AI, with significant investments in AI infrastructure expected to enhance its competitive edge and maintain high margins [9][10] - Kuaishou is recognized for its advancements in AI video generation technology, positioning it as a leading player in the domestic market [16][17] Group 3 - Xiaopeng Motors is projected to achieve substantial revenue growth, with expected revenues of 830 billion, 1494 billion, and 2229 billion RMB for 2025, 2026, and 2027 respectively, alongside a path to profitability by 2026 [23] - The report discusses the strategic focus of Xiaopeng Motors on building a platform-based technology foundation to enhance its competitive advantage in the electric vehicle market [27] - The report anticipates that the Robotaxi business of Cao Cao Mobility will benefit from the ongoing transformation of the ride-hailing market, with projected revenues of 206.7 billion, 262.4 billion, and 323.7 billion RMB for 2025 to 2027 [30] Group 4 - Horizon Robotics is noted for its leadership in automotive intelligent driving solutions, with a significant market opportunity as the penetration of high-level autonomous driving increases [35] - The report highlights the commercial potential of the pharmaceutical company Kelun-Biotech, with ongoing clinical trials and product registrations expected to drive growth [41] - The report emphasizes the robust pipeline and financial health of Hutchison China MediTech, with expectations for revenue growth driven by successful commercialization of existing products [51][52] Group 5 - China Petroleum & Chemical Corporation is positioned to benefit from regulatory changes aimed at standardizing and scaling the refining industry, with expectations for improved cash flow and dividend yield [70][74] - The report discusses the food and beverage company Guoquan's strategic expansion into rural markets, with plans to open 1,000 new stores, reflecting a strong growth trajectory [78][79]

Core Viewpoint - Since September, domestic investors have increased their holdings in pharmaceutical stocks through the Hong Kong Stock Connect, while foreign investment has slightly declined since mid-year. However, the overall trend of increasing investment in innovative drugs remains unchanged [1] Group 1: Investment Trends - Domestic investors are focusing on innovative drug stocks, while foreign investors are also increasing their positions in high-value innovative drug targets and service-related stocks, including CXO companies and "AI + healthcare" concepts [1] - The upcoming ESMO conference in mid to late October is expected to be a catalyst for the industry, with recommendations to focus on companies like CanSino Biologics (09926), Kelun-Biotech (06990), Rongchang Biologics (09995), and Hansoh Pharmaceutical (01276) that are expected to release significant data [1] Group 2: Recommended Sectors - The report suggests a focus on innovative drugs, highlighting companies such as 3SBio (01530) and Eucure Biopharma-B (06996) which have rich short-term catalysts and whose valuations do not yet reflect the value of their core products. Companies like Ascletis Pharma (02096), Hutchison China MediTech (000113), and Legend Biotech are considered significantly undervalued with clear long-term growth logic [1] - In the CXO sector, leading companies benefiting from high downstream demand and marginal recovery in financing, such as WuXi AppTec (02268), are recommended for attention [1]

Core Insights - The report highlights that foreign capital continues to invest in high-cost performance targets within the pharmaceutical sector, suggesting a focus on catalysts and undervalued quality innovation opportunities in Q4 [1][2] - The Hang Seng Healthcare Index increased by 3.1% this week, outperforming the broader market, with medical devices, biopharmaceuticals, and prescription drugs showing superior performance [1] - There is a notable increase in domestic capital holdings in pharmaceutical stocks through the Hong Kong Stock Connect since September, while foreign holdings have slightly decreased since mid-year, indicating a sustained interest in innovative drugs [1][2] Market Review - The report indicates that foreign investors have been increasing their positions in high-cost performance innovative drug targets and service-related companies, particularly those benefiting from potential interest rate cuts and "AI + healthcare" concepts [1] - The upcoming Nobel Prize in Physiology or Medicine awarded for research in Treg and peripheral immune tolerance is expected to further stimulate investment interest in related innovative drug companies [2] - The ESMO conference scheduled for mid to late October is highlighted as a key event, with recommendations to focus on companies like Kangfang Biotech, Kelun-Biotech, Rongchang Biopharma, and Hengrui Medicine, which are expected to release significant data [2] Investment Recommendations - The report recommends focusing on specific segments within the pharmaceutical industry, including: 1. Innovative drugs: Companies like 3SBio and Eucure Biopharma are noted for having rich short-term catalysts and valuations that do not yet reflect the value of their core products [2] 2. CXO: Companies benefiting from high downstream demand and marginal recovery in financing, such as WuXi AppTec, are highlighted as key players in this segment [2]

Core Insights - The Chinese innovative pharmaceutical industry is experiencing a golden moment, with significant advancements in global market presence and product approvals [1][2] - The number of innovative drugs in development in China is projected to reach 704 by 2024, making it the global leader in this area [3] - The trend of high-value business development (BD) transactions indicates a shift in international perception of Chinese pharmaceutical capabilities [2][5] Group 1: Market Dynamics - Chinese innovative drugs are increasingly recognized on the global stage, with major international investments and partnerships emerging [2][4] - The total value of License-out transactions for Chinese innovative drugs reached nearly $66 billion in the first half of 2025, surpassing the total for 2024 [2] - The successful launch of products like fuquintinib in over 30 countries demonstrates the growing competitiveness of Chinese pharmaceutical companies [1][3] Group 2: Financial Performance - A significant number of Chinese innovative drug companies are reporting profitability, with 75 out of 157 A-share companies being profitable [5] - The revenue from innovative products is becoming a key driver for profitability, as seen with companies like BeiGene, which reported a 45.8% increase in product revenue [5] - The strategic focus on long-term innovation and global collaboration is yielding positive financial results for companies in the sector [5][6] Group 3: Strategic Shifts - Companies are moving away from one-time BD transactions towards building sustainable capabilities for ongoing development and commercialization [7] - The decision by companies like Hutchison China MediTech to divest non-core assets reflects a commitment to strengthening their innovative drug pipeline [7] - The emphasis on core business focus and deepening source innovation is seen as essential for future growth in the competitive global market [7][8] Group 4: Future Outlook - The industry is encouraged to transition from "borrowing boats to go to sea" to "building boats to go to sea," indicating a need for self-sufficiency and innovation [8][9] - Overcoming barriers related to funding, global teams, and drug development capabilities is crucial for the success of Chinese innovative drug companies [8] - The aspiration remains for a cohort of Chinese innovative drug companies to emerge as global pharmaceutical giants in the future [9]

Core Insights - The report highlights an increasing investment trend from both domestic and foreign investors in service-oriented companies and innovative pharmaceutical firms, particularly in the context of anticipated interest rate cuts in Q4 [1][2] - The Hang Seng Healthcare Index rose by 2.2% this week, underperforming the broader market, with CXO, biopharmaceuticals, and traditional Chinese medicine sectors showing better performance [1] Investment Insights - The upcoming ESMO conference in mid-October is expected to provide significant data releases from companies such as Kangfang Biotech, Kelun-Biotech, and Rongchang Biotech, which are recommended for close monitoring [2] - With an increase in industry catalysts starting in October, the market is anticipated to rebound, focusing on the following segments: 1. Innovative drugs: Companies like 3SBio and Eucure Biopharma have rich short-term catalysts, and their valuations do not yet reflect the value of core blockbuster products. Companies like Sinopharm and Legend Biotech are considered undervalued with clear long-term growth logic [2] 2. CXO: Leading companies in this segment are expected to benefit from high downstream demand and marginal improvements in financing conditions, such as WuXi AppTec [2]

Core Viewpoint - The Hang Seng Healthcare Index increased by 2.2% last week, underperforming the broader market, with the CXO, biopharmaceutical, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Domestic investors have been increasing their holdings through the Hong Kong Stock Connect since September, while foreign investors' holdings have slightly decreased since mid-year, although both continue to focus on innovative drug companies [1] - Both domestic and foreign investors have increased their positions in service-related stocks, particularly those that may benefit from interest rate cuts, such as CXO companies [1] Group 2: Upcoming Events - The ESMO conference is scheduled for mid to late October, and the report suggests focusing on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995), which are expected to release significant data [1] Group 3: Investment Recommendations - The report recommends attention to the following sectors: 1) Innovative drugs: Companies like 3SBio (01530) and Eucure Biopharma-B (06996) have abundant short-term catalysts and their valuations do not yet reflect the value of core products; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are expected to benefit from high downstream demand and improving financing conditions [1]